Menu

In the News

Overdoses Have Killed More Than Three Times as Many People as COVID-19 in San Francisco

In this interview for the San Francisco Public Press podcast “Civic,” Dr. Hannah Snyder from PHI’s CA Bridge program describes the increase in overdose deaths during the COVID-19 pandemic, and how the program is working to advance new approaches in changing how drug users are treated.

  • San Francisco Public Press
a fast driving emergency services vehicle

While COVID-19 deaths have the potential for exponential growth due to the nature of a viral pandemic, they are dwarfed by the number of people who have died from drug overdoses in the city this year. 

As of Dec. 16, the San Francisco Department of Public Health reports that 172 people have died from COVID-19. The number of overdose deaths reported through the end of October stood at 570. There were 441 in 2019. 

Dr. Hannah Snyder, an addiction specialist at San Francisco’s general hospital and a member of the clinical leadership team at the CA Bridge Program, a project of the Public Health Institute, said the main driver of overdose death is the prevalence of the powerful opioid fentanyl. 

“A lot of overdose deaths are fentanyl and stimulants, fentanyl and heroin, fentanyl and benzodiazepines,” she said. “Those might be cases where the patient didn’t necessarily know that they were getting fentanyl. They thought they were taking benzodiazepine or a Xanax. That might not be somebody who’s used to having any opioids in their system. Or maybe it’s a more potent fentanyl analog.”

Hear the podcast

Buprenorphine, under the brand name Suboxone, is a prescription drug that can eliminate the horrific withdrawal symptoms that make it so difficult for opioid users to quit. As part of her work at the CA Bridge Program, Snyder has been a major advocate for making the medication widely available on demand in California. 

“For so long, you could only get medication for addiction treatment like buprenorphine by getting on a long waitlist and showing up in an appointment and jumping through tons of hoops,” she said. “Historically, hospitals and emergency departments didn’t treat people who use drugs very well. So people were really afraid to come in and admit use.”

Snyder advocated using this time as an opportunity to change how drug users are treated.

In the CA Bridge Program, we’ve decided that every hospital in the state of California should be a 24-7 welcoming access point for people who use drugs, where you can come in day or night and say you want to cut back or quit on your opioid use.” she said. “And we’ll help get started on buprenorphine right away, often within an hour or two. And then we’ll get you linked to ongoing life saving treatment.

Dr. Hannah Snyder, CA Bridge

If COVID-19 and drug overdoses are both deadly health crises, she believes that our responses should be similar: “Be kind and decrease stigma and just make it as easy as possible for people to get the treatment that they need and for people to stay healthy and well in the long term. And that’s the most important thing I think we can do.”

Click below to read the full story from the San Francisco Public Press.

Originally published by San Francisco Public Press


More Updates

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.

Donate

Find Employment

Begin your career at the Public Health Institute.

See Jobs

Aerial view of wildfire smoke

Close

Wildfires & Extreme Heat: Resources to Protect Yourself & Your Community

Communities across the U.S. and around the world are grappling with dangerous wildfires and extreme heat. These threats disrupt and uproot communities and pose serious risks to environmental and community health—from rising temperatures, unhealthy air pollutants, water contamination and more. Find PHI tools, resources and examples to help communities take action and promote climate safety, equity and resiliency.

Get started

Continue to PHI.org